Merck (MRK) Initiates Patient Enrollment for Global Phase 3 Extension Study of Belzutifan to Secure Long‑Term Safety
Initiation and Objectives of the Global Phase 3 Extension Study
Global pharmaceutical company Merck & Co. (MRK) has begun enrolling patients in the global Phase 3 extension trial (LITESPARK‑043) to assess the long‑term efficacy of its innovative drug belzutifan (brand name Welireg). The study will enroll approximately 450 patients with metastatic solid tumors and von Hippel‑Lindau (VHL) syndrome who previously participated in belzutifan clinical programs. The first patient enrollment was initiated on March 23, 2026, and the trial is slated for final completion on January 14, 2034, allowing for extended overall‑survival follow‑up. This strategic move by Merck aims to demonstrate long‑term survival benefits beyond short‑term efficacy, thereby strengthening its market position.
Mechanism of HIF‑2α Inhibition and Patient Benefits
Belzutifan is the first oral small‑molecule inhibitor that targets hypoxia‑inducible factor‑2α (HIF‑2α), a driver of tumor growth and angiogenesis. Inactivation of the VHL gene leads to abnormal accumulation of HIF‑2α protein in cancer cells, promoting tumor development; belzutifan directly blocks this pathway to inhibit disease progression. For patients with VHL‑associated renal cell carcinoma (RCC) and neuroendocrine tumors—who previously had limited options beyond repeated surgery—belzutifan represents a unique therapeutic hope. Merck seeks to confirm the long‑term safety of this mechanism through the extension study, thereby providing clinicians and patients with high confidence in the treatment.
Merck’s Oncology Portfolio and Revenue Growth Drivers
Welireg is positioned as Merck’s next‑generation blockbuster, generating $590 million in global revenue in 2024—a 133 % increase year‑over‑year. In the first half of 2025, sales reached $300 million, and the fourth quarter alone delivered $220 million, reflecting explosive growth. Merck expects the data generated from this Phase 3 extension to support future global indication expansions and label updates. This initiative is part of a broader pipeline strategy to secure long‑term growth as the patent for the flagship immuno‑oncology product Keytruda approaches expiration.
Competitive Landscape Shifts and Market Positioning Benefits
In the later‑line RCC market, immune‑checkpoint inhibitors and VEGF‑targeted therapies dominate, while belzutifan competes with mTOR inhibitors such as everolimus. The global Phase 3 extension offers an opportunity to objectively demonstrate efficacy and tolerability with long‑term use, cementing a dominant position in the later‑line setting. Given the rarity of VHL‑associated diseases, accumulating long‑term safety data creates a formidable barrier to entry for potential competitors. Such extended follow‑up studies address unmet medical needs while solidifying market dominance.
Belzutifan is Merck’s core oncology asset, generating $590 million in revenue in 2024 and demonstrating strong growth into 2025. Through the global Phase 3 extension trial (NCT07405164), Merck aims to secure long‑term efficacy and safety. In the short term, the study will ensure treatment continuity for the 450 patients who previously participated in belzutifan trials; in the medium to long term, data accumulated through the 2034 completion will support belzutifan as a superior standard of care for renal cell carcinoma compared with competitors such as everolimus. Amid the ongoing expansion of the VHL‑associated tumor and later‑line RCC markets, this trial is viewed as a key driver for regulatory label updates and sustained global market leadership. Moreover, as Keytruda’s patent expires, Merck expects that establishing long‑term prescribing confidence for its next‑generation cash cow will protect corporate value and create a robust barrier to entry for emerging competitors.
Source: ClinicalTrials.gov (api_ct)